BioMarin Pharmaceutical Inc. has entered into a binding global settlement and license agreement with Ascendis Pharma A/S, resolving all pending patent-related disputes. The agreement grants Ascendis a license to BioMarin's patents in exchange for significant royalty payments on net sales of Ascendis's product, Yuviwel (TransCon CNP).
Key Details
- Royalty Terms: Ascendis will pay BioMarin royalties of 20% on U.S. net sales and 18% on net sales in the European Union, Brazil, and South Korea. These payments are effective from the first commercial sale in each territory and will continue until May 2030.
- License Grant: BioMarin grants Ascendis a non-exclusive, worldwide license to its patents for the research, development, and commercialization of Yuviwel for all current and potential indications, including achondroplasia.
- Litigation Resolution: The agreement dismisses with prejudice all pending litigation between the companies relating to the BioMarin patent rights, effective August 30, 2026.